“Neoadjuvant treatment with 12 weeks of THP led to a pCR rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer at the time of surgery, compared to 33% for those with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback